Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients.
- 1 December 1989
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 7 (12), 1915-1925
- https://doi.org/10.1200/jco.1989.7.12.1915
Abstract
Twenty-eight evaluable patients with metastatic cancer refractory to standard therapy received escalating doses of muramyl tripeptide phosphatidylethanolamine (MTP-PE) (.05 to 12 mg/m2) in phosphatidylserine (PC):phosphatidylcholine (PS) liposomes (lipid:MTP-PE) ratio 250:1). Liposomal MTP-PE (L-MTP-PE) was infused over 1 hour twice weekly; doses were escalated within individual patients every 3 weeks as tolerated for a total treatment duration of 9 weeks. Routine clinical laboratory parameters, acute phase reactants and various immunologic tests were monitored at various time points during treatment. Toxicity was moderate (less than or equal to grade II) in 24 patients with chief side effects being chills (80% of patients), fever (70%), malaise (60%), and nausea (55%). In four patients L-MTP-PE treatment was deescalated due to severe malaise and recurrent fever higher than 38.8 degrees C. The maximum-tolerated dose (MTD) was 6 mg/m2. Significant (P less than .05) increases in WBC count, absolute granulocyte count, ceruloplasmin, beta 2-microglobulin, c-reactive protein, monocyte tumoricidal activity, and serum IL-1 beta were found. Significant decreases in serum cholesterol were also observed. Clearance of intravenously (iv)-infused technetium-99 (99mTc)-labeled liposomes containing MTP-PE in four patients was biphasic; gamma camera scans revealed uptake of radiolabel in liver, spleen, lung, nasopharynx, thyroid gland, and tumor (two patients). No objective tumor regression was seen. In view of its definite immunobiologic activity and lack of major toxicity, additional phase II and adjuvant trials of L-MTP-PE are warranted.This publication has 19 references indexed in Scilit:
- Nucleotide sequence of human monocyte interleukin 1 precursor cDNA.Proceedings of the National Academy of Sciences, 1984
- DELAYED-HYPERSENSITIVITY RESPONSES OF CANCER-PATIENTS TO RECALL ANTIGENS USING A NEW MULTITEST APPLICATOR1984
- CLINICAL-PHARMACOLOGY OF TC-99M-LABELED LIPOSOMES IN PATIENTS WITH CANCER1984
- ACTIVATION OF TUMORICIDAL PROPERTIES IN HUMAN-BLOOD MONOCYTES BY LIPOSOMES CONTAINING LIPOPHILIC MURAMYL TRIPEPTIDE1983
- Prostaglandin E2 modulation of human monocyte antibody-dependent cell-mediated cytotoxicity against human red blood cellsCellular Immunology, 1982
- Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide.Proceedings of the National Academy of Sciences, 1981
- Tissue distribution and tumour localization of 99m-technetium-labelled liposomes in cancer patientsBritish Journal of Cancer, 1979
- Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol depositionProceedings of the National Academy of Sciences, 1979
- CHARACTERIZATION OF COLONY-STIMULATING ACTIVITY PRODUCED BY HUMAN MONOCYTES AND PHYTOHEMAGGLUTININ-STIMULATED LYMPHOCYTES1977
- Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramideJournal of Chronic Diseases, 1960